SEC Company Response from CardioVascular BioTherapeutics, Inc. (CIK 0001303497) — Feb 10, 2005
CardioVascular BioTherapeutics, Inc. (CIK 0001303497)
Date: Feb. 10, 2005 · CIK: 0001303497 · Accession: 0001193125-05-025317
AI Filing Summary & Sentiment
File numbers found in text: 333-119199
Letter
SEC Acceleration Request
CARDIOVASCULAR BIOTHERAPEUTICS, INC.
1700 West Horizon Ridge Parkway, Suite 100
Henderson, Nevada 89012
702-248-1174
702-617-5651 Fax
February 10, 2005
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Re: Acceleration Request for Registration Statement 333-119199
Ladies and Gentlemen:
Pursuant to Rule 461(a) of the Commission, this will confirm the oral request of counsel for CardioVascular BioTherapeutics, Inc. (the “Company”) that the effectiveness of the Company’s above registration statement on Form S-1 be accelerated to 9:01 am Eastern Time on February 11, 2005, or as soon thereafter as practicable. The Company is aware of its obligations under the Securities Act of 1933, as amended, and will comply with the same. In addition, the Company hereby acknowledges that:
(a) Should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
(b) The action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
(c) The Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions, please contact the undersigned at 702-682-2555, or our counsel, David R. Decker, at 213-687-6778.
Very truly yours,
/s/ MICKAEL A. FLAA
Mickael A. Flaa,
Chief Financial Officer
cc: First Dunbar Securities Corporation
Greg Belliston, Division of Corporation Finance, SEC
[FIRST DUNBAR SECURITIES CORPORATION LETTERHEAD]
February 10, 2005
Securities and Exchange Commission
Division of Corporation Finance
Judiciary Plaza
450 Fifth Street, N.W.
Washington, D.C. 20549
Re: CardioVascular BioTherapeutics, Inc.
Registration Statement on Form S-1
File No. 333-119199
Ladies and Gentlemen:
With respect to the above-referenced Registration Statement on Form S-1 (the “Registration Statement”), and pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned hereby join in the request of CardioVascular BioTherapeutics, Inc. that the effective date of the Registration Statement be accelerated so that the Registration Statement will become effective at 9:01 a.m., Eastern Time, on Friday, February 11, 2005, or as soon as practicable thereafter.
Sincerely,
FIRST DUNBAR SECURITIES CORPORATION
Show Raw Text
CORRESP
1
filename1.htm
SEC Acceleration Request
CARDIOVASCULAR BIOTHERAPEUTICS, INC.
1700 West Horizon Ridge Parkway, Suite 100
Henderson, Nevada 89012
702-248-1174
702-617-5651 Fax
February 10, 2005
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Re: Acceleration Request for Registration Statement 333-119199
Ladies and Gentlemen:
Pursuant to Rule 461(a) of the Commission, this will confirm the oral request of counsel for CardioVascular BioTherapeutics, Inc. (the
“Company”) that the effectiveness of the Company’s above registration statement on Form S-1 be accelerated to 9:01 am Eastern Time on February 11, 2005, or as soon thereafter as practicable. The Company is aware of its obligations
under the Securities Act of 1933, as amended, and will comply with the same. In addition, the Company hereby acknowledges that:
(a) Should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it
does not foreclose the Commission from taking any action with respect to the filing;
(b) The action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing
effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
(c) The Company may not assert this action as a defense in any proceeding initiated by the Commission or any person
under the federal securities laws of the United States.
If you have any
questions, please contact the undersigned at 702-682-2555, or our counsel, David R. Decker, at 213-687-6778.
Very truly yours,
/s/ MICKAEL A. FLAA
Mickael A. Flaa,
Chief Financial Officer
cc:
First Dunbar Securities Corporation
Greg Belliston, Division of Corporation Finance, SEC
[FIRST DUNBAR SECURITIES CORPORATION LETTERHEAD]
February 10, 2005
Securities and Exchange Commission
Division of Corporation Finance
Judiciary Plaza
450 Fifth Street, N.W.
Washington, D.C. 20549
Re: CardioVascular BioTherapeutics, Inc.
Registration Statement on Form S-1
File No. 333-119199
Ladies and Gentlemen:
With respect to the above-referenced Registration Statement on Form S-1 (the “Registration Statement”), and pursuant to Rule 461 under the
Securities Act of 1933, as amended, the undersigned hereby join in the request of CardioVascular BioTherapeutics, Inc. that the effective date of the Registration Statement be accelerated so that the Registration Statement will become effective at
9:01 a.m., Eastern Time, on Friday, February 11, 2005, or as soon as practicable thereafter.
Sincerely,
FIRST DUNBAR SECURITIES CORPORATION
As Representative
/s/ ROBERT L.
CLARK
Name:
Robert L. Clark
Title:
CEO